{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:24:47Z","timestamp":1791282287997,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.ejca.2007.01.030","type":"journal-article","created":{"date-parts":[[2007,3,29]],"date-time":"2007-03-29T11:18:11Z","timestamp":1175167091000},"page":"1011-1016","source":"Crossref","is-referenced-by-count":91,"title":["Should DPD analysis be required prior to prescribing fluoropyrimidines?"],"prefix":"10.1016","volume":"43","author":[{"given":"Jane L.","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2007.01.030_bib1","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ijrobp.2006.07.1374","article-title":"Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis","volume":"66","author":"Das","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2007.01.030_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients","volume":"25","author":"Schmoll","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.01.030_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejca.2007.01.030_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00008711","article-title":"Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency","volume":"104","author":"van Kuilenburg","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.ejca.2007.01.030_bib5","first-page":"2203","article-title":"Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile","volume":"47","author":"Heggie","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib6","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2007.01.030_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1006404701008","article-title":"The oral fluorinated pyrimidines","volume":"19","author":"de Bono","year":"2001","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2007.01.030_bib8","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","article-title":"Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer Xenografts","volume":"55","author":"Ishikawa","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejca.2007.01.030_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1006\/geno.1994.1680","article-title":"Assignment of the human dihydropyrimidine dehydrogenase gene (DPYD) to chromosome region 1p22 by fluorescence in situ hybridization","volume":"24","author":"Takai","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.ejca.2007.01.030_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/geno.1998.5379","article-title":"Characterization of the human dihydropyrimidine dehyrdogenase gene","volume":"51","author":"Wei","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.ejca.2007.01.030_bib11","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1172\/JCI118830","article-title":"Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity","volume":"98","author":"Wei","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2007.01.030_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1 G>A mutation","volume":"101","author":"Van Kuilenburg","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2007.01.030_bib13","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1158\/1078-0432.CCR-04-0337","article-title":"Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells","volume":"10","author":"Noguchi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib14","doi-asserted-by":"crossref","first-page":"8699","DOI":"10.1158\/1078-0432.CCR-05-1520","article-title":"Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients","volume":"11","author":"Ezzeldin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib15","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1158\/1078-0432.CCR-06-0549","article-title":"Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency","volume":"12","author":"Yu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib16","doi-asserted-by":"crossref","unstructured":"Cancer M-AGI. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537\u201341.","DOI":"10.1200\/JCO.1998.16.11.3537"},{"key":"10.1016\/j.ejca.2007.01.030_bib17","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.1994.12.11.2248","article-title":"Population study of dihydropyrimidine dehydrogenase in cancer patients","volume":"12","author":"Etienne","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2007.01.030_bib18","first-page":"325","article-title":"Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy","volume":"4","author":"Lu","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/00007691-199904000-00002","article-title":"Dihydropyrimidine dehydrogenase activity in a Korean population","volume":"21","author":"Sohn","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ejca.2007.01.030_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1349-7006.2001.tb01100.x","article-title":"Germline mutation of dihydropyrimidine dehydrogenase gene among a Japanese population in relation to toxicity to 5-fluorouracil","volume":"92","author":"Yamaguchi","year":"2001","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib21","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1158\/1078-0432.CCR-05-0217","article-title":"Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations","volume":"11","author":"Ogura","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib22","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2125.2000.00242.x","article-title":"Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations","volume":"50","author":"Morsman","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2007.01.030_bib23","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00280-005-0174-5","article-title":"Dihydropyrimidine dehydrogenase deficiency in an Indian population","volume":"58","author":"Saif","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2007.01.030_bib24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1046\/j.1365-2125.2002.01604.x","article-title":"Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population","volume":"53","author":"Hamdy","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2007.01.030_bib25","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib26","first-page":"2832","article-title":"Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5\u2032-splice donor site of Intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls","volume":"7","author":"Raida","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.GIM.0000118061.66602.A5","article-title":"Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluoruracil toxicity in Portuguese colorectal cancer patients","volume":"6","author":"Salgueiro","year":"2004","journal-title":"Genet Med"},{"key":"10.1016\/j.ejca.2007.01.030_bib28","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1158\/1078-0432.CCR-04-1784","article-title":"Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of caucasian individuals","volume":"11","author":"Seck","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib29","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/1078-0432.CCR-06-0747","article-title":"Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with caucasians","volume":"12","author":"Mattison","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(97)00253-3","article-title":"Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity","volume":"696","author":"Johnson","year":"1997","journal-title":"J Chromatogr"},{"key":"10.1016\/j.ejca.2007.01.030_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0378-4347(99)00173-5","article-title":"Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography","volume":"729","author":"van Kuilenburg","year":"1999","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.ejca.2007.01.030_bib32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/15257770600894576","article-title":"Activity of pyrimidine degradation enzymes in normal tissues","volume":"25","author":"van Kuilenburg","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejca.2007.01.030_bib33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1349-7006.1998.tb00509.x","article-title":"Relationship between protein levels and gene expression of dihydropyrimidine dehydrogenase in human tumor cells during growth in culture and in nude mice","volume":"89","author":"Takechi","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/abio.1999.4461","article-title":"Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction","volume":"278","author":"Johnson","year":"2000","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ejca.2007.01.030_bib35","first-page":"768","article-title":"Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype","volume":"8","author":"Johnson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib36","doi-asserted-by":"crossref","unstructured":"Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2006 [in press, corrected proof].","DOI":"10.1016\/j.canlet.2006.09.006"},{"key":"10.1016\/j.ejca.2007.01.030_bib37","first-page":"79","article-title":"Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients","volume":"25","author":"Furuhata","year":"2006","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clinbiochem.2006.07.012","article-title":"Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma","volume":"40","author":"Morel","year":"2007","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ejca.2007.01.030_bib39","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/01.ftd.0000245771.82720.c7","article-title":"A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy","volume":"28","author":"Ciccolini","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ejca.2007.01.030_bib40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1177\/0091270004268911","article-title":"Important role of the dihydrouracil\/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics","volume":"44","author":"Jiang","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2007.01.030_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1570-0232(02)00239-8","article-title":"Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity","volume":"774","author":"Garg","year":"2002","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.ejca.2007.01.030_bib42","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1158\/1078-0432.CCR-03-0374","article-title":"Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test","volume":"10","author":"Mattison","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/abio.2002.5666","article-title":"A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidne dehydrogenase deficiency","volume":"306","author":"Ezzeldin","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ejca.2007.01.030_bib44","first-page":"3021","article-title":"Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity","volume":"9","author":"Ezzeldin","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/109065703322146777","article-title":"Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography","volume":"7","author":"Fischer","year":"2003","journal-title":"Genet Test"},{"key":"10.1016\/j.ejca.2007.01.030_bib46","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1373\/49.10.1661","article-title":"Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase","volume":"49","author":"Ahluwalia","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2007.01.030_bib47","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2007.01.030_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200210000-00007","article-title":"High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity","volume":"12","author":"van Kuilenburg","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejca.2007.01.030_bib49","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib50","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1158\/1078-0432.CCR-06-0320","article-title":"Pharmacogenetics of capecitabine in advanced breast cancer patients","volume":"12","author":"Largillier","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2007.01.030_bib51","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s00280-005-0139-8","article-title":"Toxic death-case after capecitabine+oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency","volume":"58","author":"Ciccolini","year":"2006","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907000950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907000950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T20:33:10Z","timestamp":1556310790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804907000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0959804907000950"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2007.01.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}